Cargando…

Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer

[Image: see text] Positron emission tomography (PET) is a sensitive modality for cancer molecular imaging. We aim to develop a PET probe for sensitive detection and risk stratification of prostate cancer by targeting an abundant microenvironment oncoprotein, extradomain-B fibronectin (EDB-FN). The p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Zheng, Sergeeva, Olga, Roelle, Sarah, Cheng, Han, Gao, Songqi, Li, Yajuan, Lee, Zhenghong, Lu, Zheng-Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2019
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356864/ https://www.ncbi.nlm.nih.gov/pubmed/30729224 http://dx.doi.org/10.1021/acsomega.8b02729

Ejemplares similares

Radionuclide Cisternography with [(64)Cu]Cu-DOTA
por: Greiser, Julia, et al.
Publicado: (2023)

PET Imaging of Hepatocellular Carcinoma Using ZD2-((68)Ga-NOTA)
por: Sergeeva, Olga, et al.
Publicado: (2023)

Positron Emission Tomography Imaging of CD105 Expression with a (64)Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA
por: Zhang, Yin, et al.
Publicado: (2011)

[(64)Cu]‐labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice
por: Schjoeth‐Eskesen, Christina, et al.
Publicado: (2015)

Comparison of the Effects of DOTA and NOTA Chelators on (64)Cu-Cudotadipep and (64)Cu-Cunotadipep for Prostate Cancer
por: Lee, Inki, et al.
Publicado: (2023)

Synthesis of DOTA-pyridine chelates for (64)Cu coordination and radiolabeling of αMSH peptide
por: Yang, Hua, et al.
Publicado: (2021)

The somatostatin receptor 2 antagonist (64)Cu-NODAGA-JR11 outperforms (64)Cu-DOTA-TATE in a mouse xenograft model
por: Rylova, Svetlana N., et al.
Publicado: (2018)

Development of an automated production process of [(64)Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications
por: Liu, Tengzhi, et al.
Publicado: (2022)

Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [(64)Cu]Cu-DOTA-TOC
por: Vahidfar, Nasim, et al.
Publicado: (2022)

Synthesis and In Vitro Comparison of DOTA, NODAGA and 15-5 Macrocycles as Chelators for the (64)Cu-Labelling of Immunoconjugates
por: Maisonial-Besset, Aurélie, et al.
Publicado: (2022)

Pre-clinical Positron Emission Tomography Reconstruction Algorithm Effect on Cu-64 ATSM Lesion Hypoxia
por: Sanghera, Bal, et al.
Publicado: (2016)

64Cu-ATSM Hypoxia Positron Emission Tomography for Detection of Conduit Ischemia in an Experimental Rat Esophagectomy Model
por: Park, Seong Yong, et al.
Publicado: (2015)

Companion Diagnostic (64)Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines
por: Lee, Helen, et al.
Publicado: (2018)

Probing Light Dark Matter with positron beams at NA64
por: Andreev, Yu.M., et al.
Publicado: (2023)

Chelator-Free (64)Cu-Integrated Gold Nanomaterials for Positron Emission Tomography Imaging Guided Photothermal Cancer Therapy
por: Sun, Xiaolian, et al.
Publicado: (2014)

Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe (64)Cu-cyclam-RAFT-c(-RGDfK-)(4)
por: Jin, Zhao-Hui, et al.
Publicado: (2012)

Inflammatory Myofibroblastic Tumor: Findings on (68)Ga-DOTA-NOC Positron-emission Tomography-Computed Tomography
por: Tripathy, Sarthak, et al.
Publicado: (2020)

Hypoglycemia-Triggered Motion Artifact on (68)Ga-DOTA-TOC Positron Emission Tomography/Computed Tomography
por: Chandra, Piyush, et al.
Publicado: (2021)

Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model
por: Ullrich, Martin, et al.
Publicado: (2016)

(64)Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
por: Higashikawa, Kei, et al.
Publicado: (2014)

(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
por: Kurihara, Hiroaki, et al.
Publicado: (2015)

Evaluation of hypoxia in a feline model of head and neck cancer using (64)Cu-ATSM positron emission tomography/computed tomography
por: Ballegeer, Elizabeth A, et al.
Publicado: (2013)

(64)Cu-DOTATATE Positron Emission Tomography (PET) of Borrelia Burgdorferi Infection: In Vivo Imaging of Macrophages in Experimental Model of Lyme Arthritis
por: Skovsbo Clausen, Anne, et al.
Publicado: (2020)

Imaging of atherosclerosis with [(64)Cu]Cu-DOTA-TATE in a translational head-to-head comparison study with [(18)F]FDG, and Na[(18)F]F in rabbits
por: Grandjean, Constance E., et al.
Publicado: (2023)

Dose predictions for [(177)Lu]Lu-DOTA-panitumumab F(ab′)(2) in NRG mice with HNSCC patient-derived tumour xenografts based on [(64)Cu]Cu-DOTA-panitumumab F(ab′)(2) – implications for a PET theranostic strategy
por: Ku, Anthony, et al.
Publicado: (2021)

A preliminary clinical trial to evaluate (64)Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer
por: Lee, Inki, et al.
Publicado: (2021)

Evaluation of [(64)Cu]Cu-NOTA-PEG(7)-H-Tz for Pretargeted Imaging in LS174T Xenografts—Comparison to [(111)In]In-DOTA-PEG(11)-BisPy-Tz
por: Poulie, Christian B. M., et al.
Publicado: (2021)

Synthesis and Cytotoxicity Evaluation of DOTA-Conjugates of Ursolic Acid
por: Kahnt, Michael, et al.
Publicado: (2019)

Pancreatic serous cystoadenoma (CSA) showing increased tracer uptake at 68-GaDOTA-peptide Positron Emission Tomography (68Ga-DOTA-peptide PET-CT): a case report
por: Nappo, Gennaro, et al.
Publicado: (2020)

Towards integration of (64)Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer
por: Jarrett, Angela M., et al.
Publicado: (2020)

Characterization and Stabilization of a New (64)Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography
por: Matsumoto, Hiroki, et al.
Publicado: (2021)

ZD6474 – clinical experience to date
por: Heymach, J V
Publicado: (2005)

Non-Invasive Imaging of Cysteine Cathepsin Activity in Solid Tumors Using a (64)Cu-Labeled Activity-Based Probe
por: Ren, Gang, et al.
Publicado: (2011)

Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using (64)Cu-labeled antibodies in a neuroblastoma mouse model
por: Maier, Florian C., et al.
Publicado: (2016)

(68)Ga-DOTA-E-[c(RGDfK)]2 positron emission tomography–computed tomography in the evaluation of hepatic hemangioendothelioma epithelioid
por: Soldevilla-Gallardo, Irma, et al.
Publicado: (2019)

Source for In Situ Positron Annihilation Spectroscopy of Thermal—And Hydrogen-Induced Defects Based on the Cu-64 Isotope
por: Bordulev, Iurii, et al.
Publicado: (2021)

Positron Emission Tomography Probes for Imaging Cytotoxic Immune Cells
por: Amgheib, Ala, et al.
Publicado: (2022)

Preparation & in vitro evaluation of (90)Y-DOTA-rituximab
por: Kameswaran, Mythili, et al.
Publicado: (2016)

Preparation and Biological Study of (68)Ga-DOTA-alendronate
por: Fakhari, Ashraf, et al.
Publicado: (2016)

Correlation between Standardized Uptake Value of (68)Ga-DOTA-NOC Positron Emission Tomography/Computed Tomography and Pathological Classification of Neuroendocrine Tumors
por: Kaewput, Chalermrat, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fhgetb0kt7qp1sg228jc5m4auk